Rice Hall James & Associates LLC Lowers Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Rice Hall James & Associates LLC reduced its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 7.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 44,730 shares of the medical equipment provider's stock after selling 3,410 shares during the quarter. Rice Hall James & Associates LLC owned about 0.07% of Lantheus worth $4,366,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in LNTH. Janus Henderson Group PLC boosted its holdings in shares of Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after buying an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC grew its holdings in Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after purchasing an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in shares of Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after purchasing an additional 435,445 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $36,183,000. Finally, Assenagon Asset Management S.A. grew its stake in shares of Lantheus by 1,196.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after buying an additional 310,301 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

NASDAQ LNTH traded up $1.75 during trading hours on Monday, hitting $83.06. The company's stock had a trading volume of 524,928 shares, compared to its average volume of 996,479. Lantheus Holdings, Inc. has a 12 month low of $73.11 and a 12 month high of $126.89. The company's 50 day simple moving average is $80.26 and its two-hundred day simple moving average is $89.91. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The company has a market cap of $5.75 billion, a P/E ratio of 23.60 and a beta of 0.12.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm's revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the company earned $1.69 EPS. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LNTH. B. Riley lowered their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Truist Financial cut their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $131.20.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.